Literature DB >> 17646986

PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.

Nathalie Labarrière1, Nadine Gervois, Annabelle Bonnin, Régis Bouquié, Francine Jotereau, François Lang.   

Abstract

Choosing a reliable source of tumor-specific T lymphocytes and an efficient method to isolate these cells still remains a critical issue in adoptive cellular therapy (ACT). In this study, we assessed the capacity of MHC/peptide based immunomagnetic sorting followed by polyclonal T cell expansion to derive pure polyclonal and tumor-reactive Melan-A specific T cell populations from melanoma patient's PBMC and TIL. We first demonstrated that this approach was extremely efficient and reproducible. We then used this procedure to compare PBMC and TIL-derived cells from three melanoma patients in terms of avidity for Melan-A A27L analog, Melan-A(26-35)and Melan-A(27-35), tumor reactivity (lysis and cytokine production) and repertoire. Regardless of their origin, i.e., fresh PBMC, peptide stimulated PBMC or TIL, all sorted populations (from the three patients) were cytotoxic against HLA-A2+ melanoma cell lines expressing Melan-A. Although some variability in peptide avidity, lytic activity and cytokine production was observed between populations of different origins in a given patient, it differed from one patient to another and thus no correlation could be drawn between T cell source and reactivity. Analysis of Vbeta usage within the sorted populations showed the recurrence of Vbeta3 and Vbeta14 subfamilies in the three patients but differences in the rest of the Melan-A repertoire. In addition, in two patients, we observed major repertoire differences between populations sorted from the three sources. We especially documented that in vitro peptide stimulation of PBMC, used to facilitate the sort by enriching in specific T lymphocytes, could significantly alter their repertoire and reactivity towards tumor cells. We conclude that PBMC which are easily obtained from all melanoma patients, can be as good a source as TIL to derive high amounts of tumor-reactive Melan-A specific T cells, with this selection/amplification procedure. However, the conditions of peptide stimulation should be improved to prevent a possible loss of reactive clonotypes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646986     DOI: 10.1007/s00262-007-0361-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells.

Authors:  Coen Govers; Cor Berrevoets; Elike Treffers-Westerlaken; Marieke Broertjes; Reno Debets
Journal:  Hum Gene Ther Methods       Date:  2012-06       Impact factor: 2.396

Review 2.  Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

Authors:  F Jotereau; N Gervois; N Labarrière
Journal:  Target Oncol       Date:  2012-02-15       Impact factor: 4.493

3.  Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy.

Authors:  Thomas Zuliani; Julien David; Sylvain Bercegeay; Marie-Christine Pandolfino; Isabelle Rodde-Astier; Amir Khammari; Cécile Coissac; Bruno Delorme; Soraya Saïagh; Brigitte Dréno
Journal:  J Transl Med       Date:  2011-05-16       Impact factor: 5.531

4.  CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells.

Authors:  Tiphaine Parrot; Romain Oger; Houssem Benlalam; Diane Raingeard de la Blétière; Nicolas Jouand; Anne Coutolleau; Laurence Preisser; Amir Khammari; Brigitte Dréno; Philippe Guardiola; Yves Delneste; Nathalie Labarrière; Nadine Gervois
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

Review 5.  Linking form to function: Biophysical aspects of artificial antigen presenting cell design.

Authors:  Karlo Perica; Alyssa K Kosmides; Jonathan P Schneck
Journal:  Biochim Biophys Acta       Date:  2014-09-06

6.  MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.

Authors:  Yann Godet; Agnès Moreau-Aubry; Yannik Guilloux; Virginie Vignard; Amir Khammari; Brigitte Dreno; Francine Jotereau; Nathalie Labarriere
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

7.  Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.

Authors:  T Ohkuri; D Wakita; K Chamoto; Y Togashi; H Kitamura; T Nishimura
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

8.  A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma.

Authors:  N Labarriere; A Fortun; A Bellec; A Khammari; B Dreno; S Saïagh; F Lang
Journal:  Clin Dev Immunol       Date:  2013-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.